论文部分内容阅读
目的对比观察临床应用TA方案与CAF方案治疗术后乳腺癌的疗效及经济性。方法选取2006年5月至2012年5月确诊为乳腺癌在我院行术后化学治疗的病历75例,其中使用TA方案治疗的35例(n=35),使用CAF方案治疗的40例(n=40),评价两组疗效、毒性反应并进行药物经济学比较。结果 TA组总有效率为82.87%,CAF组总有效率为65.00%,两组比较差异有显著性(P<0.05);两组患者主要不良反应为恶心呕吐、脱发、贫血、中性粒细胞减少、心脏毒性和肝功能异常,程度较轻,均能耐受。两组患者各种不良反应的发生率未见显著性差异,均为(P>0.05);CAF组每增加1个效果单位仅需药品成本39.77元,明显优于TA组的127.65元。结论 TA方案的疗效优于CAF方案,但CAF方案有利于减轻患者负担,可作为低收入乳腺癌患者的首选辅助化学治疗方案。
Objective To compare the curative effect and economy of breast cancer treated with TA and CAF regimen. Methods From May 2006 to May 2012, 75 patients with breast cancer who underwent chemotherapy in our hospital were enrolled. Among them, 35 patients (n = 35) were treated with TA regimen, 40 patients treated with CAF regimen n = 40). Efficacy and toxicity of the two groups were evaluated and their pharmacological economics were compared. Results The total effective rate was 82.87% in TA group and 65.00% in CAF group, with significant difference between the two groups (P <0.05). The main adverse reactions were nausea and vomiting, alopecia, anemia, neutrophil Reduce, cardiotoxicity and liver dysfunction, to a lesser extent, can tolerate. There was no significant difference in incidence of various adverse reactions between the two groups (P> 0.05). For each additional unit of efficacy in CAF group, the cost of drugs was only 39.77 yuan, which was significantly better than that of TA group (127.65 yuan). Conclusion The efficacy of TA regimen is better than that of CAF regimen. However, CAF regimen is helpful to reduce the burden on patients and may be the preferred adjuvant chemotherapy regimen for low-income breast cancer patients.